Takeda commits to advancing treatments for rare bleeding disorders and cancer
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to advancing treatments for rare bleeding disorders.
These scientific updates from the company showed off investigational and early-stage therapies as well as data from Phase 3 trials in disease states like leukemia and lymphoma.
Phil Rowlands, Takeda’s head at the Oncology Therapeutic Area Unit, said: “We are presenting notable data on several clinical programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients.”
Takeda also presented its portfolio of treatments for rare bleeding disorders, including haemophilia A, B and von Wilibrand disease. It presented updates to its gene therapy programmes designed to deal with these types of diseases.
Daniel Curran, Head of Takeda’s Rare Diseases Therapeutic Area Unit, said: “Understanding real-world evidence is critical as Takeda continues to provide patients with innovative therapies for hemophilia A and hemophilia B while broadening our research and development efforts in von Willebrand disease and other bleeding disorders.”
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …
ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …